公开(公告)号：US20240279358A1

公开(公告)日：2024-08-22

申请号：US18570888

申请日：2022-06-15

Applicant: ALECTOR LLC

Inventor： Seung-Joo LEE ,  Tarangsri NIVITCHANYONG ,  Wei-Hsien HO ,  Wei LI ,  Marina K. ROELL ,  Spencer LIANG

IPC: C07K16/40 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/40 ,  A61P35/00 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/35 ,  C07K2317/53 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure is generally directed to compositions that include monovalent antibodies, e.g., monoclonal monovalent antibodies that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK polypeptide or human MerTK polypeptide, and use of such compositions in treating an individual in need thereof.

公开(公告)号：US20240279341A1

公开(公告)日：2024-08-22

申请号：US18570865

申请日：2022-06-15

Applicant: ALECTOR LLC

Inventor： Seung-Joo LEE ,  Tarangsri NIVITCHANYONG ,  Wei-Hsien HO ,  Wei LI ,  Marina K. ROELL ,  Spencer LIANG

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/40

CPC classification number: C07K16/2827 ,  A61P35/00 ,  C07K16/40 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure is generally directed to compositions that include bispecific antibodies, e.g., monoclonal antibodies, that specifically bind a MerTK polypeptide (e.g., a mammalian MerTK or human MerTK) and a PDL1 polypeptide (e.g. a mammalian PDL1 polypeptide or human PDL1 polypeptide), and use of such compositions in treating an individual in need thereof.

公开(公告)号：US20250145709A1

公开(公告)日：2025-05-08

申请号：US19015556

申请日：2025-01-09

Applicant: Alector LLC

Inventor： Patricia CULP ,  Seung-Joo LEE ,  Helen LAM ,  Wei-Hsien HO ,  Arnon ROSENTHAL

IPC: C07K16/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20240076362A1

公开(公告)日：2024-03-07

申请号：US18310207

申请日：2023-05-01

Applicant: Alector LLC

Inventor： Jeonghoon SUN ,  Wei-Hsien HO ,  Muhammad A. ALHAWAGRI ,  Philip Ling KONG ,  Herve RHINN ,  Hua LONG ,  Karpagam SRINIVASAN ,  Ananya MITRA ,  Daniel P. BERMINGHAM ,  Klaus-Dieter HEGER ,  Santiago Viveros SALAZAR ,  Francesca CIGNARELLA ,  Ilaria TASSI ,  Tina SCHWABE ,  Angie Grace YEE ,  Arnon ROSENTHAL

IPC: C07K16/18

CPC classification number: C07K16/18 ,  A61K2039/505

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20240383997A1

公开(公告)日：2024-11-21

申请号：US18621575

申请日：2024-03-29

Applicant: ALECTOR LLC

Inventor： Eric BROWN ,  Hamid SALIMI ,  Wei-Hsien HO ,  Leonard PRESTA ,  Margaret TANG ,  Jeonghoon SUN

IPC: C07K16/28 ,  A61K49/00 ,  C07K16/18 ,  G01N33/50

Abstract: Provided herein are engineered constant domains that have been engineered to comprise a blood brain barrier (BBB)-binding region, such a CDRH3 from an antibody that binds to a blood brain barrier target. Such engineered constant domains can be within a full length antibody or an antigen-binding fragment of an antibody such that the antibody or fragment is capable of binding to both the antigen of the antibody or fragment and the BBB target and is capable of being transported across the BBB.

公开(公告)号：US20210317208A1

公开(公告)日：2021-10-14

申请号：US17272083

申请日：2019-08-30

Applicant: Alector LLC

Inventor： Patricia CULP ,  Helen LAM ,  Wei-Hsien HO ,  Leonard G. PRESTA ,  Arnon ROSENTHAL

IPC: C07K16/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20210246204A1

公开(公告)日：2021-08-12

申请号：US16972840

申请日：2019-06-07

Applicant: Alector LLC

Inventor： Patricia CULP ,  Seung-Joo LEE ,  Helen LAM ,  Wei-Hsien HO ,  Arnon ROSENTHAL

IPC: C07K16/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20210079074A1

公开(公告)日：2021-03-18

申请号：US16943123

申请日：2020-07-30

Applicant: Alector LLC

Inventor： Jeonghoon SUN ,  Wei-Hsien HO ,  Muhammad A. ALHAWAGRI ,  Philip Ling KONG ,  Herve RHINN ,  Hua LONG ,  Karpagam SRINIVASAN ,  Ananya MITRA ,  Daniel P. BERMINGHAM ,  Klaus-Dieter HEGER ,  Santiago Viveros SALAZAR ,  Francesca CIGNARELLA ,  Ilaria TASSI ,  Tina SCHWABE ,  Angie Grace YEE ,  Arnon ROSENTHAL

IPC: C07K16/18

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.